EP. 1: Overview of the DESTINY-Breast06 Study
Panelists discuss the results and implications of the DESTINY-Breast06 study, highlighting the efficacy of trastuzumab deruxtecan in patients with HER2-positive breast cancer previously treated with multiple lines of therapy.
EP. 2: Overview of the DESTINY-Breast12 Study
Panelists discuss the findings from the DESTINY-Breast12 study, focusing on the efficacy and safety of trastuzumab deruxtecan in patients with HER2-low breast cancer and its potential to expand treatment options for this subgroup.
EP. 3: Overview of the PATINA Study
Panelists discuss the PATINA study, examining the role of palbociclib in combination with letrozole as a first-line treatment for hormone receptor–positive, HER2-negative breast cancer, and its impact on progression-free survival.
